Mission Seal US Department of State
United States Mission to Germany flag graphic
U.S. Policy and Issues
Policy News
News from Washington
German-American Relations
U.S. Policy Texts in German (Amerika Dienst)
Receive Policy Texts by Email
InfoAlert
Latest Issue
International Security
Transatlantic Relations
Trade & Economics
U.S. Politics & Government
Development
Environment
U.S. Society
U.S. Culture
InfoAlert Archive
- by Topic
- by Issue
Electronic Journals

InfoAlert

 

Bad Medicine in the Market
Bate, Roger and Kathryn Boateng
Health Policy Outlook, AEI, posted June 9, 2007, online edition, 6p
"Counterfeit medicines are an insidious threat to global health, and the risks they pose have been largely underestimated to date. Apart from failing to cure disease, they can cause mental and physical damage—and even death. Fake drugs containing insufficient active ingredients breed resistance, which can make standard drugs useless. The problem is disproportionately severe in developing and emerging-market countries, which also have the highest burden of infectious diseases. Countries have the primary responsibility—both in stopping criminal manufacturing and distribution and in protecting their citizens from counterfeit products—but multilateral organizations such as the World Health Organization (WHO) must do more to expose the problem and help countries tighten regulatory controls. While monitoring of outright fakes is improving and arrests of those trading in them are increasing, some global agencies are promoting drugs they assume to be good copies of branded drugs but which are probably substandard. Global agencies must stop this double standard and develop effective methods of improving detection of all substandard products." Roger Bate is a resident fellow at AEI. Kathryn Boateng is a research assistant at AEI.
Go to the article

H10/04-07 posted July 10, 2007

back to top ^

United States Mission